Interestingly, our results were consistent with those of an earlier study that also observed that SIGMAR1 silencing increased the sorafenib sensitivity of hepatocellular carcinoma cells in vitro and in vivo [18]. The gene discussed is SIGMAR1; the disease is hepatocellular carcinoma.